Treatment Landscape in HR+, HER2- MBC

 

Insights from 2023 ESMO Annual Meeting
S

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

By Insights from 2023 ESMO Annual Meeting FEATURING Sara Tolaney, Hope Rugo
By Insights from 2023 ESMO Annual Meeting FEATURING Sara Tolaney, Hope Rugo
1,057 views
November 3, 2023
1 Comment
Login to view comments. Click here to Login
Treatment Landscape in HR+, HER2- MBC
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
08:40
PrecisCa

Managing Common Toxicities From CDK4/6i

Feat. E. Shonkwiler
08:51
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Effects of Ovarian Ablation or Suppressio…

Feat. R. Gray
05:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Results of the Phase 3 SAFE Trial -…

Feat. C. Becherini, L. Livi
06:55
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Comparative OS of Pts in Trials of CKD4/6…

Feat. C. Kappel
13:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Subgroup Analysis of the RIGHT Choice Tri…

Feat. N. El Saghir
19:21
Abirami Sivapiragasam

Sequencing Treatment Options for HR+ mBC

12:44
SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice…

Feat. Y. Lu
19:12
Penn Medicine Abramson Cancer Center

Updates in HR+ mBC

Feat. I. Makhlin
17:31
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Case Studies Discussion of Patients with HR+/HER2- mBC

Feat. N. Hunter
26:03
Total Health

HR+ mBC: Optimizing Endocrine Therapy

Feat. J. O'Shaughnessy
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
19:02
Denise Yardley

Phase III Pooled MONALEESA Safety & Efficacy Data in HR+/HER2- m…

10:43
Ahmad Awada

Recent Development in the Treatment of HR+/HER2- mBC

22:17
RWJBarnabas Health Rutgers Cancer Institute of New Jersey

Administration, Safety, and Dosing of Ribociclib for ER+/HER2- mBC

Feat. J. Lauria
08:31
Neelam Desai

Comparing the Efficacy Data of CDK4/6i in HR+/HER2- mBC

13:35
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The RIGHT Choice Trial - 1L Ribociclib + E…

Feat. H. Azim
12:08
West Cancer Center

Patient Selection for CDK4/6i in HR+/HER2- Advanced BC

Feat. G. Vidal